Cullinan Therapeutics, Inc.
CGEM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $42 | $61 | $41 | $40 |
| G&A Expenses | $14 | $15 | $14 | $15 |
| SG&A Expenses | $14 | $15 | $14 | $15 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $56 | $76 | $55 | $55 |
| Operating Income | -$56 | -$76 | -$55 | -$55 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $5 | $6 | $6 | $8 |
| Pre-Tax Income | -$51 | -$70 | -$49 | -$48 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$51 | -$70 | -$49 | -$48 |
| % Margin | – | – | – | – |
| EPS | 0 | -1.19 | -0.82 | -0.81 |
| % Growth | 100% | -45.1% | -1.2% | – |
| EPS Diluted | 0 | -1.19 | -0.82 | -0.81 |
| Weighted Avg Shares Out | 59 | 59 | 59 | 59 |
| Weighted Avg Shares Out Dil | 59 | 59 | 59 | 59 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $6 | $7 | $8 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$51 | -$76 | -$55 | -$55 |
| % Margin | – | – | – | – |